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Voltage-gated sodium channels are known to play a pivotal role in perception and
transmission of pain sensations. Gain-of-function mutations in the genes encoding the
peripheral neuronal sodium channels, hNav1.7–1.9, cause human painful diseases.
Thus while treatment of chronic pain remains an unmet clinical need, sodium
channel blockers are considered as promising druggable targets. In a previous
study, we evaluated the analgesic activity of sumatriptan, an agonist of serotonin
5HT1B/D receptors, and some new chiral bioisosteres, using the hot plate test in the
mouse. Interestingly, we observed that the analgesic effectiveness was not necessarily
correlated to serotonin agonism. In this study, we evaluated whether sumatriptan and
its congeners may inhibit heterologously expressed hNav1.7 sodium channels using
the patch-clamp method. We show that sumatriptan blocks hNav1.7 channels only
at very high, supratherapeutic concentrations. In contrast, its three analogs, namely
20b, (R)-31b, and (S)-22b, exert a dose and use-dependent sodium channel block.
At 0.1 and 10 Hz stimulation frequencies, the most potent compound, (S)-22b, was
4.4 and 1.7 fold more potent than the well-known sodium channel blocker mexiletine.
The compound induces a negative shift of voltage dependence of fast inactivation,
suggesting higher affinity to the inactivated channel. Accordingly, we show that (S)-
22b likely binds the conserved local anesthetic receptor within voltage-gated sodium
channels. Combining these results with the previous ones, we hypothesize that use-
dependent sodium channel blockade contributes to the analgesic activity of (R)-31b
and (S)-22b. These later compounds represent promising lead compounds for the
development of efficient analgesics, the mechanism of action of which may include a
dual action on sodium channels and 5HT1D receptors.
Keywords: pain, Nav1.7, use-dependent sodium channel block, analgesia, sumatriptan analogs, mexiletine
Introduction
Neuropathic pain arises as a direct consequence of a lesion or disease aﬀecting the somatosensory
system (Treede et al., 2008). Voltage-gated sodium channel have a major role in the generation
and conduction of the electrical pain information in the central and peripheral nervous system
(Dib-Hajj et al., 2010; Catterall, 2012). The Nav1.7, Nav1.8, and Nav1.9 sodium channel isoforms,
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which are preferentially expressed in dorsal root ganglia (DRG)
and trigeminal neurons, have been shown to be involved in
physiological and pathological pain sensation (Dib-Hajj et al.,
2013). Accordingly, gain-of-function mutations in the genes
encoding these channels induce DRG neuron hyperexcitability
and cause human painful disorders, while loss-of-function
mutations of Nav1.7 cause congenital insensitivity to pain
(Hoeijmakers et al., 2015). These observations strongly suggest
a promising role for sodium channels as druggable targets in pain
treatment (Cummins and Rush, 2007; Priest and Kaczorowski,
2007; Dib-Hajj et al., 2009; Theile and Cummins, 2011).
Treatment of neuropathic pain is an unmet medical problem,
commonly characterized by resistance to conventional analgesics,
such as acetaminophen, non-steroidal anti-inﬂammatory drugs,
and low opioid doses. Currently, treatment of neuropathic pain
is based on the use of tricyclic antidepressants, mixed serotonin-
noradrenaline reuptake inhibitors, and antiepileptics, followed by
opioids and voltage-gated sodium channel blockers (Attal et al.,
2010; Jongen et al., 2013; Finnerup et al., 2015). Interestingly,
a number of these drugs are able to exert, through a primary
or secondary mechanism of action, a blockade of voltage-
gated sodium channels (Haeseler et al., 2006; Dick et al., 2007;
Wang et al., 2010b; Leﬄer et al., 2012; Stoetzer et al., 2015).
We also recently demonstrated that orphenadrine, a muscle
relaxant with analgesic properties, partially inhibits peripheral
nerve sodium channels at clinical concentrations (Desaphy et al.,
2009).
Although serotonin is considered as a critical modulator of
pain transmission, its role in chronic pain is not completely
understood because of the involvement of a large number of
cellular targets and receptor subtypes, which may exert pro-
or anti-nociceptive actions (Lopez-Garcia, 2006). Interestingly,
it has been recently shown that the antinocieptive eﬀect of
serotonin on peripheral neuropathic pain is likely mediated by
speciﬁc activation of 5HT2B receptor (Urtikova et al., 2012).
Conversely, it is widely acknowledged that the 5HT1B/1D receptor
agonists, such as sumatriptan, exert a selective action on cranial
pain and migraine. Besides this central action, the triptans were
also shown to attenuate pain-related behavior in rodent models
of somatic and visceral pain, but lacked eﬃcacy in models of
peripheral neuropathic pain (Kayser et al., 2002; Nikai et al.,
2008). In a previous study, we showed that sumatriptan and
some newly synthesized chiral bioisosteres display analgesic
activity in the mouse hot plate test (Carocci et al., 2010).
Some analogs showed a greater analgesic proﬁle compared to
sumatriptan, but this activity was not necessarily correlated to
serotonin agonism. Because their chemical structure contains an
aryloxyethylamine backbone, which is also present in the sodium
channel blocker mexiletine, we wondered whether the in vivo
analgesic eﬀects of sumatriptan and its novel derivatives may
be related to inhibition of sodium channels expressed in the
peripheral nervous system.
In this study, we evaluated the eﬀects of sumatriptan and
three of its newly synthesized analogs [namely 20b, (R)-31b, (S)-
22b; Figure 1] on hNav1.7 functionally expressed in HEK293
cells, using the patch-clamp method. We also compared their
eﬀects on sodium currents with those of mexiletine. We found
FIGURE 1 | Chemical structures of sumatriptan and its bioisosteres,
compared to mexiletine. All the compounds share a common backbone
shown in red, which consists of an aromatic moiety linked to a protonable
amine group through an alkyl bridge.
that, whereas sumatriptan inhibits sodium channels only at high,
supratherapeutic concentrations, all the three analogs were more
potent than mexiletine in blocking sodium channels. We further
demonstrate that the most potent compound, (S)-22b, likely
binds to the conserved local anesthetic receptor within the pore
of voltage-gated sodium channels, since the F1586C mutation
in hNav1.4, which is likely involved in the high-aﬃnity binding
of local anesthetics to inactivated sodium channels (Ragsdale
et al., 1996; Desaphy et al., 2012), greatly reduces sodium current
inhibition by the compound, zeroing the use-dependence. Since
(R)-31b and (S)-22b displayed a greater analgesic activity than
sumatriptan in the hot plate test (Carocci et al., 2010), we
hypothesize that the blockade of DRG sodium channels is likely
involved in the mechanism of action of the bioisosteres. On an
other hand, the limited analgesic potency of sumatriptan in the
hot plate test may rely on its diﬃculty to cross the blood brain
barrier, due to its negative Log D, and its limited activity on
sodium channels. We thus propose the compounds (S)-22b and
(R)-31b as potential starting compounds for the synthesis of new
drugs which could be useful in the treatment of chronic pain.
Materials and Methods
Cell Culture and Patch-Clamp Recordings
Permanent expression of PNS hNav1.7 sodium channel subtype,
skeletal muscle hNav1.4 subtype, and its F1586C mutant
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was obtained in human embryonic kidney (HEK293) cells as
previously described (Desaphy et al., 2009, 2010).
Sodium currents (INa) were recorded using the patch-clamp
technique in whole-cell conﬁguration at room temperature (21–
22◦C), using Axopatch 1D ampliﬁer (Axon Instruments, Union
City, CA, USA). Voltage-clamp protocols and data acquisition
were performed with pCLAMP software (version 10.3, Axon
Instr.) through a 12-bit A–D/D–A interface (Digidata 1440A,
Axon Instr.). Patch pipettes had resistance ranging from 1 to
3 M. Currents were low-pass ﬁltered at 2 kHz (−3 dB) by
the four-pole Bessel ﬁlter of the ampliﬁer and were digitized
at 10–20 kHz as previously described (Desaphy et al., 2009,
2010, 2012). In the whole-cell conﬁguration, a 25-ms long
test pulse at −30 mV was applied from the holding potential
(HP) of −120 mV at a low frequency until stabilization of INa
amplitude and kinetics was achieved (typically 5 min). Only
those data obtained from cells exhibiting series resistance errors
<5 mV were considered for analysis. Capacitance currents were
partially compensated using the ad hoc circuit of the ampliﬁer.
Residual capacitance transients and leak currents were eliminated
oﬀ-line by subtraction of the scaled passive current response
recorded upon return to the HP. After reaching stable INa, a
maximum of two drug concentrations were tested on each cell,
to minimize the possible bias due to INa run-down. Typically,
a single cell experiment did not last more than 30 min, which
is associated to a run-down of peak current amplitude lower
than 10% (mean ± SEM, 6.2 ± 0.7%, n = 10). Concentration–
response curves were thus drawn by combining results obtained
in various cells at both stimulation frequencies and ﬁt with
Eq. 1: IDRUG/ICTRL = 1/{1 + ([Drug]/IC50)nH}, where IC50 is the
concentration needed to produce a 50% reduction of INa and nH
is the slope factor.
To characterize the voltage dependency of steady-state
channel activation, currents were evoked by 25 ms-long voltage
steps ranging from −100 to+70 mV, applied in 5 mV increments
every 10 s. The HP was −150 mV to be sure having all the
channels available for opening. The conductance (GNa) values
were calculated from measured peak INa currents and calculated
reversal potential for sodium ions (ENa = +68.4 mV) using
Eq. 2: GNa = INa/(V−ENa). Resulting values for conductance were
normalized to the maximal conductance and plotted as a function
of voltage. The relationships were ﬁtted using the Boltzmann
Eq. 3: GNa/GNa,max = 1/{1 + exp[(V − V50)/K]}, where GNa,max
is the maximal conductance, K is the slope factor, and V50 is the
potential at which half of the channels are activated.
The voltage dependency of steady-state fast inactivation
(channel availability) was determined using a two-pulse protocol.
The HP was −160 mV; conditioning voltage steps were applied
for 50 ms from −120 to −20 mV, in 10-mV increments,
and followed by a test pulse at −20 mV for 20 ms. The
normalized peak current amplitude measured during the test
pulse was plotted as a function of the conditioning pulse
voltage. The relationships were ﬁtted using the Boltzmann
Eq. 4: INa/INa,max = 1/(1 + exp[(V−Vh)/S]), where INa,max
is the maximal current amplitude, S is the slope factor,
and Vh is the potential at which half of the channels are
inactivated.
Statistical Analysis
Averaged experimental points are reported as means ± SEM
from at least three patches. The ﬁt parameters of averaged
relationships are given together with the SE of the regression.
Because the concentration–response curves were obtained by
combining results obtained in diﬀerent cells at the various
concentrations, the statistical comparison of INa inhibition by
the diﬀerent exploratory compounds was performed at each
concentrations using analysis of variance (ANOVA) followed
by ad hoc Bonferroni’s t-test. On the other hand, to perform
statistical analysis of (S)-22b eﬀects on activation and fast
inactivation, the complete voltage-dependence relationships were
obtained in each cells, and the ﬁt parameters obtained in each
cells were averaged as means ± SEM from eight cells. Statistical
analysis was performed using paired Student’s t-test. Statistical
signiﬁcance was deﬁned as p < 0.05.
Drugs and Solutions
The patch pipette solution contained in mM: 120 CsF, 10 CsCl,
10 NaCl, 5 EGTA, and 5 HEPES, and the pH was adjusted to
7.2 with CsOH, while the bath solution contained in mM: 150
NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5 HEPES, and 5 glucose and
pH was adjusted to 7.4 with NaOH. Sumatriptan and its analogs
were synthesized in our laboratories as previously described in
details (Carocci et al., 2010). Sumatriptan was synthesized as
succinate salt, while (R)-31b, 20b and (S)-22b as hydrochloride
salts. Mexiletine was purchased from Sigma–Aldrich (Milan,
Italy). All the compounds were solubilized directly in bath
solution to obtain the desired ﬁnal concentrations. To test drugs,
the patched cells were ﬁrst exposed to a continuous stream of
control bath solution and later exposed to a continuous stream
of drug-supplemented bath solution, ﬂowing out from a plastic
capillary.
Results
Sumatriptan and its analogs, as well as mexiletine, were tested
on hNav1.7 channels permanently expressed in HEK293 cell line.
Sodium currents were recorded using the patch-clamp technique
in whole-cell conﬁguration, before and after the application
of drugs. The currents were elicited by depolarizing the cell
membrane from the HP of −120 to −30 mV at two stimulation
frequencies, 0.1 Hz and 10 Hz, to determine both tonic and phasic
blocks. Figure 2A illustrates the time course of Nav1.7 current
amplitude in a representative cell during application of 30 µM
(S)-22b. Before drug application, peak current amplitude was
stable at 0.1 Hz frequency (open circles, ﬁrst arrow in Figure 2A).
Increasing the stimulation frequency to 10 Hz slightly reduced
current amplitude by less than 10% (cyan circles, second arrow in
Figure 2A; mean ± SEM, 9.8 ± 0.8%, n = 56 cells). Application
of the drug reduced the peak current amplitude by 17.9%
(17.6 ± 3.9%, n = 3) on ﬁrst voltage step with respect to control
(third arrow in Figure 2A) and further gradually reduced sodium
current at 0.1 Hz (red circles). At the steady-state reached after
about 3 min, the peak current amplitude was 69.6% of control
(fourth arrow in Figure 2A; 71.9 ± 4.8%, n = 3). Applying
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FIGURE 2 | Effects of exploratory compounds on hNav1.7 channels at
0.1 Hz and 10 Hz, to determine tonic and phasic block, respectively.
(A) Time course of peak sodium current amplitude in a representative
HEK293 cell permanently transfected with hNav1.7, before and during
application of 30 µM (S)-22b, and after drug washout. The membrane was
held at –120 mV and depolarized to –30 mV for 25 ms at 0.1 or 10 Hz
stimulation frequency. The numbered arrows correspond to effects described
in the text. (B) Typical sodium current traces recorded in the same cell as in
(A), which were obtained from the average of three records obtained at
steady state in control at 0.1 Hz (corresponding to arrow 1 in A), and in
presence of 30 µM (S)-22b at 0.1 Hz (arrow 4 in A) and 10 Hz (arrow 5
in A). (C–F) Representative sodium current traces recorded as in (A,B), after
application of 1 mM sumatriptan, 30 µM of 20b and (R)-31b compounds,
and 100 µM mexiletine.
10 Hz stimulation, the drug induced a huge and rapid use-
dependent inhibition of sodium currents by 53% (59.3 ± 6.7%,
n = 3). At steady state, the peak current amplitude in presence
of the drug was 34.2% of control current measured at 10 Hz
(ﬁfth arrow in Figure 2A; 35.1 ± 6.6%, n = 3). The eﬀects
of 10 Hz stimulation frequency and drug were fully reversible,
since the current amplitude after washout was 93.3% of control
current recorded before drug application (90.9 ± 1.9%, n = 3).
Figure 2B shows representative sodium current traces recorded
in the same cell as in Figure 2A at steady-states before and
after the application of 30 µM (S)-22b at both stimulation
frequencies. Representative current traces obtained using the
same protocols are shown for mexiletine, sumatriptan, and its
derivatives. Sumatriptan showed a lower aﬃnity to the channel
compared to all other compounds: 1 mM sumatriptan exerted
23.6 ± 3.2% (n = 3) inhibition at 0.1 Hz and 23.9 ± 3.1%
(n = 3) inhibition at 10 Hz. A 30 µM concentration of 20b and
(R)-31b produced a similar tonic block (11.6 ± 0.8% (n = 4)
and 14.9 ± 2.4% (n = 3), respectively), while use-dependence
was accentuated with 36.0 ± 3.1% (n = 4) and 44.4 ± 3.2%
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(n = 3) inhibition at 10 Hz, respectively. Mexiletine at the
concentration of 100 µM produced an eﬀect similar to 30 µM
(R)-31b, with 13.2 ± 1.5% and 42.0 ± 2.8% (n = 4) inhibition
at 0.1 and 10 Hz, respectively. As for (S)-22b, the eﬀects of all
drugs were quite reversible (not shown). The concentration–
response curves (Figure 3) were constructed from the eﬀects
measured in diﬀerent cells at the various concentrations using
similar protocols and were ﬁtted with Eq. 1 (see Materials and
Methods) to determine the IC50 values (Table 1). Statistical
analysis was performed using ANOVA followed by ad hoc
Bonferroni’s t-test to compare the percentage of inhibition of
sodium currents exerted by the various drugs at 30, 100, 300,
and 1000 µM (Table 2). Sumatriptan appeared as a very weak
blocker of hNav1.7 sodium channels and did not display any
use-dependence. In contrast, the three analogs blocked hNav1.7
currents at concentrations more similar to those of the well-
known sodium channel blocker, mexiletine. Indeed, 20b, (R)-31b,
and (S)-22b were 2.6, 2.9, and 4.4 fold more potent at 0.1 Hz than
mexiletine. The compound (S)-22b was signiﬁcantly more potent
than the others compounds at both 0.1 and 10 Hz. The use-
dependent behavior of drugs, expressed as the ratio of IC50 values
calculated at 0.1 and 10 Hz, were very similar for mexiletine,
(S)-22b, and (R)-31b.
Eﬀects of the more potent (S)-22b were examined on the
voltage dependence of Nav1.7 activation and fast inactivation.
The current–voltage relationship was determined in eight cells
expressing hNav1.7 channels, before and after application of
100 µM (S)-22b, by depolarizing the membrane from –100 to
+70 mV for 25 ms, in 5 mV increments, every 10 s (Figure 4A,
left protocol). The HP was –150 mV. A representative example
of current traces recorded in the absence and presence of (S)-22b
is shown in Figure 4B. The averaged I–V relationships (n = 8)
are shown in Figure 4C. The drug did not change the voltage
to elicit maximal current amplitude (between –20 and –15 mV),
but drastically reduced current amplitude at voltage superior
to –30 mV. The voltage dependence of steady-state channel
activation was obtained from the I–V curves and ﬁt with Eq. 3
(Figure 4D). The half-maximum activation potential (V50) and
the slope factor (K) were not signiﬁcantly modiﬁed by the drug
(V50 = –30.7 ± 1.5 mV and K = –4.2 ± 0.3 mV in CTRL;
V50 = –33.5 ± 1.8 mV and K = –4.8 ± 0.3 mV in presence of
drug; mean ± SEM, n = 8; not signiﬁcant with paired Student’s
t-test). The voltage dependence of steady-state fast inactivation
was determined using the two-pulse protocol shown in Figure 4A
(right). The HP was –160 mV; cell membrane was depolarized
for 50 ms from −120 to −20 mV, in 10-mV increments; a test
pulse was applied at −20 mV for 20 ms. The relationships were
constructed by reporting the normalized peak current amplitude
measured during the test pulse as a function of the prepulse test
voltage. The averaged relationships (n = 8) and Boltzmann ﬁts
with Eq. 4 are shown in Figure 4D. The drug induced a signiﬁcant
8.8 mV negative shift of the half-maximum inactivation potential
(Vh) from −57.5 ± 1.8 to −66.3 ± 3.3 mV (mean ± SEM, n = 8;
P < 0.01 with paired Student’s t-test). The slope factor (S) was not
signiﬁcantly altered by the drug (S = 8.1 ± 0.5 mV in CTRL and
8.3 ± 0.3 mV in presence of drug, n = 8).
Use-dependent block and shift of fast inactivation voltage
dependence are characteristics of many clinically used sodium
channel blockers, including the antiarrhythmic mexiletine. These
drugs are thought to bind the local anesthetic molecular receptor
located within the ion-conducting pore of sodium channels,
involving amino acid residues of the transmembrane S6 segment
of domain IV. The putative local anesthetic receptor is very
well conserved among sodium channel subtypes, including
hNav1.7 and the skeletal muscle hNav1.4 subtype (Figure 5A).
A conserved phenylalanine residue (Phe1586 in hNav1.4) is
especially critical for high-aﬃnity binding to inactivated channels
and use-dependent block (Ragsdale et al., 1996; Desaphy et al.,
2009, 2012). To verify whether (S)-22b binds to the same
site as local anesthetics, we thus tested the drug on wild-
type and mutated (F1586C) hNav1.4, permanently transfected
in HEK293 cells (Desaphy et al., 2010, 2012). Representative
FIGURE 3 | Concentration–response relationships for mexiletine,
sumatriptan, and its three analogs on hNav1.7 channels. The curves
were constructed at 0.1 and 10 Hz frequency stimulations from peak
amplitude values of sodium currents recorded as described in Figure 2,
and fitted with Eq. 1 given in the “Materials and Methods” section. Each
data point is the mean ± SEM of at least three cells. The fit parameters
together with the SE of the regression are given in Table 1. Statistical
analysis is reported in Table 2.
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TABLE 1 | Comparison between half-maximum inhibitory concentrations of sumatriptan and its analogs on hNav1.7 sodium channels and of (S)-22b on
wild-type and mutated hNav1.4.
Drug 0.1 Hz 10 Hz 0.1 Hz/10 Hz IC50 ratio
IC50 (µM) nH IC50 (µM) nH
hNav1.7
Sumatriptan 2399 ± 56 1.4 ± 0.1 2187 ± 106 1.4 ± 0.1 1,1
20b 127 ± 16 1.2 ± 0.2 54 ± 4 1.1 ± 0.1 2,4
(R)-31b 118 ± 5 1.4 ± 0.1 39 ± 3 1.1 ± 0.1 3,0
(S)-22b 77 ± 10 1.3 ± 0.2 21 ± 2 1.3 ± 0.1 3,7
Mexiletine 338 ± 18 1.4 ± 0.1 114 ± 12 1.0 ± 0.1 3,0
hNav1.4
(S)-22b 51 ± 2 1.4 ± 0.1 12 ± 1 1.3 ± 0.1 4,3
hNav1.4 – F1586C
(S)-22b 215 ± 5 1.4 ± 0.1 175 ± 9 1.4 ± 0.1 1,2
The values were obtained from the fit of the concentration–response curves illustrated in Figures 2 and 5. The half-maximum inhibitory concentration (IC50) and the slope
factor (nH) are given as the fit value ± SE of the fit.
TABLE 2 | Statistical analysis (ANOVA) of hNav1.7 sodium channel inhibition by exploratory compounds at the holding potential (HP) of –120 mV, at 0.1 Hz
(A) and 10 Hz (B) stimulation frequencies.
Sumatriptan Mexiletine 20b (R)-31b
A: 0.1 Hz
Mexiletine yes
yes yes
20b yes ns yes
yes yes yes yes
(R)-31b yes ns yes ns ns
yes yes yes yes ns ns
(S)-22b yes yes yes yes ns yes ns
yes yes yes yes yes ns yes ns
B: 10 Hz
Mexiletine yes
yes yes
20b yes yes yes
yes yes yes yes
(R)-31b yes yes yes ns ns
yes yes yes yes yes ns
(S)-22b yes yes yes yes yes yes yes
yes yes yes yes yes ns ns ns
The percentages of inhibition of sodium channels by the various drugs at each concentration, as reported in concentration–response relationships (Figure 3), were
compared using ANOVA followed by ad hoc Bonferroni’s t-test. The significance is reported as “yes” (at least p < 0.05) or “ns” (not significant) in cyan cells (for
comparison at 30 μM), yellow cells (100 μM), orange cells (300 μM), and pink cells (1000 μM). Note that sumatriptan was not tested at 30 μM (gray cells).
hNav1.4 and F1586C sodium current traces recorded before and
after application of 30 µM (S)-22b are shown in Figure 5B. The
(S)-22b compound resulted less potent on F1586C mutant, as
well as less use-dependent, with respect to wild-type channels.
At 30 µM concentration, (S)-22b exerted a 25% blocking activity
at 0.1 Hz and a 74% blocking activity at 10 Hz on WT hNav1.4,
compared to 13% at 0.1 Hz and 16% at 10 Hz on F1586C.
The dose–response curves (Figure 5C) show the greatly reduced
potency of (S)-32b and the total lack of use-dependence on
F1586C at 0.1 Hz. Fit parameters are given in Table 1. This result
indicate that Phe1586 is critically involved in the high-aﬃnity
binding of (S)-22b to inactivated sodium channels.
Discussion
Using the patch-clamp technique to evaluate the eﬀects of
sumatriptan and its analogs on peripheral neuronal sodium
channels, we observed that sumatriptan is a weak sodium
channel blocker, since the concentration necessary to produce
a signiﬁcant sodium current reduction is greater than 100 µM,
whereas the therapeutic blood concentration range is 61–203 nM
(Schulz and Schmoldt, 2003). In addition, sumatriptan did not
display any use-dependent behavior. In contrast, we observed
that three recently reported analogs of sumatriptan exert a
substantial block of hNav1.7 sodium currents, greater than
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FIGURE 4 | Effects of 100 µM (S)-22b on the voltage dependence of
hNav1.7 channels. (A) Left protocol, to obtain the current–voltage (I–V) and
activation relationships, the membrane was held at –150 mV and depolarized
by successive 25 ms-long voltage steps ranging from –100 to +70 mV
applied in 5-mV increments every 10 s. Right protocol, to obtain the voltage
dependence of steady state availability (fast inactivation), the membrane was
held at –160 mV, and conditioning 50 ms-long voltage steps were applied
from –120 to –20 mV in 10-mV increments, before to apply a 20 ms-long
test pulse at –20 mV. (B) Families of sodium currents recorded in a
representative cell using the left protocol shown in (A), in control conditions
(CTRL) and at steady state during the application of 100 µM (S)-22b.
(C) Averaged I–V relationships obtained using the left protocol shown in (A).
In each tested cell, the peak current amplitude measured in CTRL and in
presence of 100 µM (S)-22b was normalized with respect to maximal peak
current amplitude recorded in CTRL. Each point value is the mean ± SEM
calculated from eight cells. (D) The voltage dependence of activation
(triangles) was drawn by reporting the normalized conductance, calculated
from the I–V curves with Eq. 2, as a function of test pulse voltage and fitted
with Eq. 3. The voltage dependence of channel availability (circles) was
drawn by reporting the normalized peak sodium current amplitude measured
during the test pulse as a function of conditioning pulse voltage (right
protocol in A), and fitted with Eq. 4. Each point value is the mean ± SEM
calculated from eight cells. The averaged fit parameters, calculated from the
relationships obtained in each cells, are reported in the text.
the one exerted by the well-known sodium channel blocker
mexiletine. The compounds were 2.5-to-4 fold more potent
than mexiletine in blocking sodium currents at 0.1 and 10 Hz
stimulation, displaying a similar use-dependent behavior. The
most potent (S)-22b compound induced a signiﬁcant negative
shift of voltage dependence of steady-state inactivation, as
many local anesthetic-like drugs. Accordingly, we demonstrated
that (S)-22b binds sodium channels at the conserved local
anesthetics receptor site, since it shows a reduced potency
and a total absence of use-dependence when applied to the
hNav1.4 F1586Cmutant compared to wild-type hNav1.4 channel.
Thus, (S)-22b could be considered as a true local anesthetic-like
drug.
Probably, the chemical structure of sumatriptan – containing a
sulfonamide group, an aromatic ring consisting in an indolic ring,
and an ethylic chain – impedes high aﬃnity binding to sodium
channels. It should be noted that sumatriptan is little lipophilic,
displaying a negative Log D-value at pH 7.4 (Rance et al., 1997),
which likely limits its inhibitory activity on sodium channels
(Desaphy et al., 2012). In contrast, the sumatriptan analogs
include a naphthyloxy group linked to a protonable amine
through an alkyl chain, which are pharmacophoric elements
commonly found in other known sodium channel blockers, such
as propranolol (Desaphy et al., 2003; Wang et al., 2010a). The
three compounds show a Log D-value greater than unity at
pH 7.4 (Carocci et al., 2010). Like propranolol, the sumatriptan
analogs are more potent than mexiletine, most probably because
the naphthyl moiety increases steric hindrance and lipophilia
with respect to the xylyl one in mexiletine (Desaphy et al.,
2012). Compared to 20b, the constraint of the nitrogen atom
into a pyrrolidine ring as in (R)-31b slightly improves use-
dependence, in agreement with previous studies, in which we
demonstrated that the constriction of the N atom of tocainide
in a pyrrolidine enhances binding aﬃnity to sodium channels
in the inactivated state (De Luca et al., 2003). Interestingly, the
introduction of a methyl in C2 close to the oxygen, as in (S)-
22b, allows a greater gain of blocking activity at both stimulation
frequencies.
Using the hot plate test on mice, we have previously
demonstrated that sumatriptan and its analogs induce analgesia
in vivo (Carocci et al., 2010). At the dose of 30 mg/kg, (R)-
31b showed the greatest analgesic eﬃcacy lasting for 45 min,
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FIGURE 5 | Effects of (S)-22b on wild-type hNav1.4 channels and
F1586C mutant. (A) Amino acid alignment of hNav1.7 and hNav1.4 using
Clustal W 2.0 shows high conservation of the putative local anesthetic
receptor located within the sixth segment of domain IV. The phenylalanine
residue in red box (F1586 in hNav1.4 and F1737 in hnav1.7) is thought to be
critical for the binding of local anesthetics to inactivated sodium channels.
(B) Representative traces of sodium currents recorded as in Figure 2 in
HEK29 cells permanently transfected with wild-type hNav1.4 or F1586C
hNav1.4 mutant. The inhibitory effects of 30 µM (S)-22b were greatly reduced
in the F1586C mutant. (C) Concentration–response relationships for (S)-22b
at 0.1 and 10 Hz stimulation frequencies were obtained as in Figure 3, and
fitted with Eq. 1. Each data point is the mean ± SEM of at least three cells. At
both stimulation frequencies, the inhibition of F1586C channels by (S)-22b
was significantly minor with respect to that of WT channels at 30, 100, 300,
and 1000 µM (at least P < 0.05 with unpaired Student’s t-test). The fit
parameters together with the SE of the regression are given in Table 1.
but (S)-22b displayed signiﬁcant analgesia lasting at least for
75 min. At the same concentration, the analgesic eﬃcacy of
sumatriptan and 20b were more modest. At 10 mg/kg, only
(S)-22b exerted signiﬁcant analgesia, appearing as the most
potent compound. It should be noted that the doses tested
in this previous study are quite high (Carocci et al., 2010).
While sumatriptan was shown to exert antinociceptive eﬀects
in a rat model of trigeminal neuropathic pain at the clinically
relevant dose of 0.1 mg/kg s.c. (Kayser et al., 2002), it remains
to be veriﬁed whether (S)-22b may produce analgesia at lower
doses.
In the same study, we also demonstrated that the chemical
maneuvers on sumatriptan analogs resulted in signiﬁcant
alterations of their serotonergic proﬁle: Compared to
sumatriptan, 20b displayed a 2.5- and 3.6-fold reduced
aﬃnity toward 5HT1B and 5HT1D receptors, respectively;
(R)-31b conserved agonism only toward 5HT1D receptor
(twofold reduction compared to sumatriptan) but showed a
13-fold reduced aﬃnity toward 5HT1B; in contrast, (S)-22b was
associated with a drastically reduced aﬃnity to both serotonergic
receptors (eightfold reduction toward 5HT1B and 360-fold
reduction toward 5HT1D). Thus the analgesic activity measured
in the mouse was not correlated to binding aﬃnities to serotonin
receptors, suggesting that at least part of the analgesic eﬀect of
the new compounds is not mediated by serotonergic agonism.
Combining the pharmacological results obtained in the
present study with those obtained in vivo and in binding aﬃnity
studies (Figure 6), we hypothesize that the analgesic activities
of (S)-22b and (R)-31b result, at least in part, from their ability
to block sodium channels at the higher frequency. In addition,
5HT1D serotonergic agonism may also contribute to (R)-31b
analgesic activity. On the other hand, the weak in vivo analgesic
proﬁle showed by sumatriptan may rely in part on its weak
activity on sodium channels. Another likely important limiting
factor for sumatriptan analgesic eﬀects is its low lipophilia,
which may reduce its permeability across the blood brain barrier.
Indeed, intrathecal administration of sumatriptan low doses
was shown to reduce persistent inﬂammatory pain in mice
(Nikai et al., 2008). Thus the increase lipophilia of (S)-22b
and (R)-31b might be advantageous for reaching signiﬁcant
analgesia in vivo. Finally, we suggest that 20b displays an
analgesic activity comparable to sumatriptan, because it may not
gain enough use-dependent sodium channel blocking activity.
It is worth to note that the apparent aﬃnity for sodium
channel blockade may appear lower than the binding aﬃnity to
serotonergic receptors, but the patch-clamp experiments likely
underestimate the actual aﬃnity for use-dependent INa inhibition
in a physiopathological condition, which is characterized by
less negative resting membrane voltage and high-frequency
discharges of action potentials.
FIGURE 6 | Cartoon depicting hypothesis regarding pharmacological
actions of exploratory compounds displaying analgesic activity in
vivo, based on the results obtained in the present and previous studies
(Carocci et al., 2010). The thickness of the arrows indicates the intensity of
the analgesic activity exerted by the compounds.
Frontiers in Pharmacology | www.frontiersin.org 8 July 2015 | Volume 6 | Article 155
Carbonara et al. hNav1.7 block by new sumatriptan analogs
Conclusion
Our results suggest that (S)-22b and (R)-31b could be considered
as eﬃcient sodium channel blockers associated with a signiﬁcant
antihyperalgesic proﬁle. It should be kept in mind that, as
most sodium channel blockers, these compounds may act on
various sodium channel isoforms (at least hNav1.4 in this
study) and that use-dependence is a critical issue for safety.
It should be mentioned that targeting either speciﬁc isoforms
or activities of sodium channels (or both), all may be valid
strategies to develop treatment of pain syndromes (Theile
and Cummins, 2011). Although maintaining a residual 5HT1D
activity, (R)-31b probably lacks of clinically relevant activity
on 5HT1B receptors. It is noteworthy that 5HT1B agonism
may be associated with the cardiovascular side eﬀects usually
observed with triptans, which limits their clinical use in patients
who suﬀer from cardiac diseases. Thus, (S)-22b and (R)-31b
could represent interesting lead compounds for the synthesis
of new analgesic drugs the mechanism of action of which
can involve potent and use-dependent blockade of sodium
channels or a dual action on sodium channels and 5HT1D
receptors.
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